Neuren Pharmaceuticals Limited (NURPF) Financials

NURPF Assets vs Liabilities
DateAssetsLiabilities
Dec. 31, 2025 228.9 million 2.9 million
June 30, 2025 217.8 million 5.2 million
Dec. 31, 2024 254.6 million 28.5 million
June 30, 2024 152.3 million 6.0 million

NURPF Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Dec. 31, 2025 -1.9 million ?
June 30, 2025 84.4 million 336698
Dec. 31, 2024 5.8 million 289560
June 30, 2024 -13.7 million 510539

NURPF Net Income
Graph available only for paid members. Upgrade to see it.
DateNet Income
Dec. 31, 2025 10.3 million
June 30, 2025 9.9 million
Dec. 31, 2024 83.3 million
June 30, 2024 5.3 million

NURPF Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Dec. 31, 2025 197.7 million - -
June 30, 2025 197.0 million - -
Dec. 31, 2024 138.1 million - -
June 30, 2024 142.3 million - -

NURPF Shares Outstanding

No data available :(

NURPF Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Dec. 31, 2025 21365 14.4 million 2.5 million -
June 30, 2025 3288 9.8 million 1.6 million -
Dec. 31, 2024 4349 9.4 million 1.4 million -
June 30, 2024 2002 11.9 million 1.6 million -

NURPF Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Dec. 31, 2025 24.3 million 8011
June 30, 2025 18.6 million 9.8 million
Dec. 31, 2024 119.6 million 9.4 million
June 30, 2024 16.2 million 11.9 million

NURPF

Price: $8.88

52 week price:
7.70
14.80

Earnings Per Share: 0.16 USD

P/E Ratio: 53.28

Exchange: PNK

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 1.1 billion

Links: